Publicaciones en colaboración con investigadores/as de Charité (311)

2024

  1. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

    The Lancet Oncology, Vol. 25, Núm. 1, pp. 46-61

  2. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

    The Lancet Oncology, Vol. 25, Núm. 1, pp. 29-45

  3. High prevalence of venous thrombotic events in Cushing’s syndrome: data from ERCUSYN and details in relation to surgery

    European Journal of Endocrinology, Vol. 190, Núm. 1, pp. 75-85

  4. What benefit-risk trade-offs are acceptable to rheumatoid arthritis patients during treatment selection? Evidence from a multicountry choice experiment

    RMD Open, Vol. 10, Núm. 1

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Challenges in the management of the kidney allograft: from decline to failure: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

    Kidney International

  3. Comparison of the Accuracy of the 7-Item HADS Depression Subscale and 14-Item Total HADS for Screening for Major Depression: A Systematic Review and Individual Participant Data Meta-Analysis

    Psychological Assessment, Vol. 35, Núm. 2, pp. 94-114

  4. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  5. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database

    JAMA dermatology, Vol. 159, Núm. 8, pp. 837-847

  6. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  7. EAACI guidelines on the diagnosis of IgE-mediated food allergy

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 12, pp. 3057-3076

  8. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

    Leukemia, Vol. 37, Núm. 7, pp. 1521-1529

  9. Erratum : World Allergy Organization Anaphylaxis Guidance 2020 [Japanese Journal of Allergology Vol.70 (2021) No.9 p.1211-1234]

    Arerugi = [Allergy], Vol. 72, Núm. 3, pp. 314

  10. Food-Induced Anaphylaxis: Data From the European Anaphylaxis Registry

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 7, pp. 2069-2079.e7

  11. Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database

    Rheumatology (Oxford, England), Vol. 62, Núm. 4, pp. 1559-1567

  12. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study

    The Lancet Oncology, Vol. 24, Núm. 2, pp. 187-194

  13. Imbalance in Bone Morphogenic Proteins 2 and 7 Is Associated with Renal and Cardiovascular Damage in Chronic Kidney Disease

    International Journal of Molecular Sciences, Vol. 24, Núm. 1

  14. Influence of Early Postoperative Basal Insulin Treatment and Post-Transplant Diabetes Mellitus Risk on Health-Related Quality of Life in Kidney Transplant Recipients—An Analysis of Data From a Randomized Controlled Trial

    Transplant International, Vol. 36

  15. Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study

    Investigational New Drugs, Vol. 41, Núm. 5, pp. 677-687

  16. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    European Urology